Leela Barham

Harmonised health technology assessment in Europe? There’s a long way to go

https://pharmaphorum.com/views-analysis-market-access/harmonised-health-technology-assessment-in-europe-theres-a-long-way-to-go/

Has the UK been best place in the world to invest in life sciences?

https://pharmaphorum.com/views-and-analysis/uk-best-place-world-invest-life-sciences/

Could the PPRS support a changing growth and innovation agenda?

https://pharmaphorum.com/views-and-analysis/pprs-support-changing-growth-innovation-agenda/

Bureaucracy and duplication: the reality of the PPRS

https://pharmaphorum.com/views-and-analysis/bureaucracy-duplication-pprs/

Improved access? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/improved-access-reality-pprs/

What is ‘affordable’? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-impact-drug-budget/

Unstable and unpredictable? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-pharmaceutical-price-regulation-scheme/

Just how much does the NHS spend on medicines?

https://pharmaphorum.com/views-and-analysis/nhs-medicines-spend/

Three NICE thresholds for cost-effectiveness: does that make sense?

https://pharmaphorum.com/views-and-analysis/three-nice-thresholds-for-cost-effectiveness-does-that-make-sense/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search